CD44 and cancer: We observed that the relatively rapid motility along endothelial cells by MB-231 cancer cells was inhibited by treatment with antibodies against CD44 and RHAMM, and that the combinatorial effect on MB-231 cell velocity in Matrigel was greater than the effect of each Ab alone.